At Synthomics we focus on driving innovation at the most basic level of oligo synthesis, ultimately enabling the delivery of genomic solutions to previously unmet markets, while enhancing their overall clinical utility . Quality, low cost oligonucleotides are a key neccesity of modern Omics-tech, and Synthomics’ products will further enable their global proliferation into fields such as Research, Diagnostics, Pharma, and Agriculture for applications such as PCR, Next Generation Sequencing, Gene Synthesis, and Gene Editing.
Synthomics was founded by a group of Stanford researchers with the goal of improving biological research and the quality of medical treatment by making the most fundamental research tools as affordable as possible.
By leveraging the experience with the first major advancements in multiplexing oligonucleotide synthesis (1) and subsequent advances in automation efficiency and cost reductions (2, 3, 4, 5), Synthomics has developed a novel, highly efficient RNA and DNA synthesizer that produces oligonucleotides at dramatically lower cost and higher throughput than any other system on the market.
Advances in RNA and DNA synthesis are expected to have a direct impact on the cost and scope of important research and clinical areas including the construction of synthetic genes, the direct use of oligonucleotides in gene therapy, and used as probes in the detection and analysis of disease genes.
After successful completion of a Phase I pilot study, funded by NHGRI’s SBIR program, Synthomics applied for and was awarded a Phase II grant that funds completion of the synthesizer prototype, called the “Green Machine”, which synthesizes oligonucleotides in a 1,536-well format.
- 1) http://www.pnas.org/content/92/17/7912.long
- 2) http://www.sciencedirect.com/science/article/pii/S0168165613005324
- 3) http://www.sciencedirect.com/science/article/pii/S0168165614001618
- 4) http://www.tandfonline.com/doi/abs/10.1080/15257770.2010.534757
- 5) http://pubs.acs.org/doi/abs/10.1021/jo071087a?journalCode=joceah
Scientific Advisory Board
Ronald W. Davis is a professor in Biochemistry and Genetics at Stanford University, and is the Director of the Stanford Genome Technology Center. An early pioneer in genetics, Dr. Davis is known for several ground-breaking contributions to genetics. Dr. Davis and colleagues were the first to discover R-loops, which allowed researchers to pinpoint coding RNAs for the first time, and later were some of the first to demonstrate the function of restriction endonucleases and their ability to cut and recombine DNA fragments. These discoveries directly fueled the birth of modern genetic engineering. Dr. Davis later co-invented techniques to map genomes, which directly enabled the Yeast and Human Genomes to be fully sequenced. More recently, Dr. Davis and collaborators invented the DNA microarray, which enabled genome-wide functional studies of gene function that were previously impossible, and has been instrumental in the invention and commercialization of several technologies, including the first high throughput oligonucleotide synthesizers, charge-based sequencing of DNA, and embryonic genetic testing. Dr. Davis has over 30 biotechnology patents and over 400 peer reviewed publications. In October, 2013, Davis was listed in The Atlantic as one of the greatest innovators currently working: “A substantial number of the major genetic advances of the past 20 years can be traced back to Davis in some way.”
Dr. Lebl graduated from The University of Chemical Technology, Prague Czech Republic (1974). He holds a PhD in organic chemistry from the Institute of Organic Chemistry and Biochemistry of the Czechoslovak Academy of Sciences in Prague (1978). Dr. Lebl is the inventor of the tilted centrifugation method of oligonucleotide synthesis, which he developed at Trega Biosciences, Inc. Dr. Lebl was able to raise funds to develop this technology through SBIR grants from NIH. The technology was licensed exclusively to the Spyder Instruments, Inc. This company was formed in 1993 with Dr. Richard Houghten and Dr. Jutta Eichler. Spyder Instruments was merged, in 2000, with a new startup Illumina, Inc. (NASDAQ: ILMN) where he worked until 2012 as the Senior Director of Automation and developed what the highest throughput oligonucleotide synthesizers ever produced. Dr. Lebl has published over 230 scientific papers and he is the co-inventor of over 50 patents. In 1990 he was awarded the Leonidas Zervas Award by the European Peptide Society for distinguished contributions to the field of peptide chemistry. In 2003 he received the Jouan Award from Association for Laboratory Automation for contributions to laboratory automation and laboratory process improvement.
Dr. Perbost graduated from The University of Montpellier in Montpellier, France (1987). He holds a PhD in Nucleic Acid Chemistry from The University of Montpellier (1992). Dr. Perbost is an Organic Chemist with broad industrial experience. He has invented new technologies and driven the development process to yield a commercial product; examples include DNA sequencing flowcells, DNA and Protein microarrays, Genomic Bead Assays and DNA synthesizers. In industry his experience has been deeply rooted in the biotechnology. Starting his career at Isis Pharmaceuticals with a postdoctoral under the guidance of Yogesh Sanghvi, he focused on innovative synthesis methods of oligonucleotides. As a Senior Scientist of Genset /Merck Serono, he working on novel methods for oligonucleotide synthesis and instrumentation development. At HP/Agilent (NASDAQ: A) Dr. Perbost served as a member the technical staff inventing and developing their inkjet DNA array technology, as well building out a complete microarray manufacturing facility in Santa Clara, CA. As Group Leader at Molecular Staging Inc./ QIAGEN N.V. (NASDAQ: QGEN) he supervised a R&D team which was responsible for production of circular and linear oligonucleotide products and reduced the manufacturing cost of the production pipeline. As a Senior Scientist at CyVera he was instrumental in developing the technology that lead to the acquisition of CyVera by Illumina, Inc. (NASDAQ: ILMN). At Illumina he was part of the team that designed and developed one of the world’s largest large scale oligonucleotide synthesizer. As well being part of the technology development in surface chemistry, wafer and glass dicing operations for next gen sequencing chemistry applications. Dr. Perbost is the inventor/co-inventor of 21 patents issued in DNA & Chemical Synthesis. He is currently focused on using his expertise to make a difference developing new products or instruments for the Biotechnology industry.
Dr. Mulligan is a scientist and executive with over twenty years of management and line experience in drug discovery, technology development and commercialization, company formation and intellectual property. He was the founder or co-founder of four companies, two in synthetic biology and two in drug discovery. His publication record includes 22 peer-reviewed papers and he is an inventor on 23 issued patents. The patents reflect some of the breadth of his experience, including an antibody therapeutic, novel drug targets, software, two laboratory instruments, DNA synthesis methods, and a new class of reporter molecules for multiplexed analyte detection. At Darwin Molecular he led a research groups focused on genetics-based drug-target discovery and co-discovered an osteoporosis drug target. An antibody that neutralizes the osteoporosis target (Romosozumab, AMG 785) is in Phase III trials at Amgen. He founded Blue Heron Biotechnology to commercialize automated molecular biology and sold the company to Origene in 2010. After a brief engagement at an IP and business development consulting group, Dr. Mulligan invented a glucose-responsive insulin, founded Glycostasis, Inc. to develop the technology and sold the company to Eli Lilly. He is currently the founder and CEO of Good Therapeutics, Inc., a drug discovery startup that is developing allosterically-regulated protein drugs for use in immuno-oncology and auto-immune disease.
Keith has over 20 years of experience in automated DNA synthesis, having managed synthesis production at startup companies, and at the Stanford Genome Technology Center working under the direction of the esteemed Dr. Ronald Davis. Most recently, Keith worked on a notable advancement in DNA synthesis by developing a novel 1,536-well synthesizer technology. Additionally, Keith has diverse professional experience including the development of in situ inkjet microarrays while he was at Protogene Laboratories, and development of PCR emulsion technologies and PCR miniaturization devices at Stanford and Applied Biosystems. Keith also has extensive experience in the application of unique surface chemistries and chemical linkers as a collaboration between Stanford and CTGen, Inc, and has extensive experience prototyping and integrating multi-well liquid handling platforms.
Guillermo is a veteran in automation and process development in the field of biotechnology, establishing sample prep procedures for Next-Gen sequencing platforms, optimized synthesis protocols for use on universal supports, and the design of novel instrumentation used in both the sequencing and DNA synthesis fields. Having worked with several technologies from their beginnings in research and development and transferring those designs to manufacturing, Guillermo is familiar with the needs of the end-user and incorporates this knowledge into his designs from the beginning. Guillermo is the VP of engineering at Synthomics.